Mark D. Minden
- Hematology top 0.02%
- Acute Myeloid Leukemia Research 244
- Chronic Myeloid Leukemia Treatments 89
- Hematopoietic Stem Cell Transplantation 34
- Genetics top 0.1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 43
- Chronic Lymphocytic Leukemia Research 39
- Oncology top 0.2%
- Cancer Research top 0.2%
- Immunology top 0.5%
-
- Acute Lymphoblastic Leukemia research 85
-
- Histone Deacetylase Inhibitors Research 42
- Protein Degradation and Inhibitors 34
- Co-authors
- John E. DickTsvee LapidotJosef VormoorChristian SirardBarbara MurdochMichael A. CaligiuriTrang HoangJulio Roberto Cáceres‐Cortés
- Cited by
- HematologyGeneticsOncology
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Mark D. Minden
483 papers receiving 23.2k citations
Hit Papers
Peers
Comparison fields: 5 of 169
- Hematology 8.3k
- Genetics 2.9k
- Oncology 7.0k
- Cancer Research 3.7k
- Immunology 4.0k
Countries citing papers authored by Mark D. Minden
This map shows the geographic impact of Mark D. Minden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Minden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Minden more than expected).
Fields of papers citing papers by Mark D. Minden
This network shows the impact of papers produced by Mark D. Minden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Minden. The network helps show where Mark D. Minden may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark D. Minden, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 6 | |
| 3 | 2023 | 8 | |
| 4 | 2022 | 11 | |
| 5 | 2020 | 27 | |
| 6 | 2020 | 20 | |
| 7 | 2019 | 23 | |
| 8 | 2018 | 8 | |
| 9 | 2017 | 80 | |
| 10 | 2017 | 31 | |
| 11 | 2016 | 15 | |
| 12 | 2015 | 134 | |
| 13 | 2014 | 64 | |
| 14 | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemiabreakdown → | 2012 | 818 |
| 15 | 2010 | 46 | |
| 16 | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsbreakdown → | 2010 | 558 |
| 17 | 2010 | 56 | |
| 18 | 2008 | 24 | |
| 19 | 2007 | 29 | |
| 20 | 2006 | 46 |
About Mark D. Minden
Mark D. Minden is a scholar working on Hematology, Genetics and Oncology, having authored 509 papers that have together received 23.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (244 papers), Chronic Myeloid Leukemia Treatments (89 papers), Acute Lymphoblastic Leukemia research (85 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (42 papers), Chronic Lymphocytic Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Protein Degradation and Inhibitors (34 papers). The work is most often cited by research in Hematology (8.3k citations), Genetics (2.9k citations) and Oncology (7.0k citations). Mark D. Minden has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include John E. Dick, Tsvee Lapidot, Josef Vormoor, Christian Sirard, Barbara Murdoch, Michael A. Caligiuri, Trang Hoang, Julio Roberto Cáceres‐Cortés, Bruce M. Paterson and Aaron D. Schimmer. Their work appears in journals such as Blood, Leukemia Research, Leukemia, Cancer Research and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.